Jonathan Bones

This paper combines metabolic and cellular glycoengineering to control mAb β1,4-galactosylation, achieving broad tunable control and improved pharmacological activity.

This paper describes a dual genetic engineering strategy to enhance mAb β4-galactosylation in CHO cells, achieving over 90% galactosylation and reducing Man5 glycans without affecting mAb titre.

This study evaluates lectin-based surface profiling as a predictor of mAb product glycosylation in CHO cells following targeted glycogene engineering.

The paper identifies microprotein impurities in mAb drug products from CHO cells using Ribo-seq and mass spectrometry, showing their abundance varies with growth phase.